193 related articles for article (PubMed ID: 21594564)
1. A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia.
Tahara H; Takagi H; Sato K; Shimada Y; Tojima H; Hirokawa T; Ohyama T; Horiuchi K; Naganuma A; Arai H; Kakizaki S; Mori M
J Gastroenterol; 2011 Aug; 46(8):1010-9. PubMed ID: 21594564
[TBL] [Abstract][Full Text] [Related]
2. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization.
Foruny JR; Blázquez J; Moreno A; Bárcena R; Gil-Grande L; Quereda C; Pérez-Elías MJ; Moreno J; Sánchez J; Muriel A; Rodriguez-Sagrado MA; Moreno S
Eur J Gastroenterol Hepatol; 2005 Nov; 17(11):1157-64. PubMed ID: 16215426
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C.
Kondo C; Atsukawa M; Tsubota A; Shimada N; Abe H; Itokawa N; Nakagawa A; Fukuda T; Matsushita Y; Nakatsuka K; Kawamoto C; Iwakiri K; Aizawa Y; Sakamoto C
Intern Med; 2015; 54(2):119-26. PubMed ID: 25743001
[TBL] [Abstract][Full Text] [Related]
4. Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia.
Takahara M; Miyake Y; Miyatake H; Imagawa A; Nakatsu M; Ando M; Hirohata M; Yamamoto K
Intern Med; 2011; 50(22):2731-6. PubMed ID: 22082883
[TBL] [Abstract][Full Text] [Related]
5. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
Aizawa N; Enomoto H; Takashima T; Sakai Y; Iwata K; Ikeda N; Tanaka H; Iwata Y; Saito M; Imanishi H; Iijima H; Nishiguchi S
J Gastroenterol; 2014 Aug; 49(8):1253-63. PubMed ID: 24065124
[TBL] [Abstract][Full Text] [Related]
6. Partial splenic embolization and peg-IFN plus RBV in liver transplanted patients with hepatitis C recurrence: safety, efficacy and long-term outcome.
Bárcena R; Moreno A; Foruny JR; Blázquez J; Graus J; Riesco JM; Blesa C; García-Hoz F; Sánchez J; Gil-Grande L; Nuño J; Fortún J; Rodriguez-Sagrado MA; Moreno A
Clin Transplant; 2010; 24(3):366-74. PubMed ID: 19863593
[TBL] [Abstract][Full Text] [Related]
7. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
9. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Okada K; Kainuma M; Kajiwara E; Takahashi K; Satoh T; Hayashi J
J Viral Hepat; 2013 Dec; 20(12):838-46. PubMed ID: 24304453
[TBL] [Abstract][Full Text] [Related]
10. Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis.
Tamai H; Mori Y; Shingaki N; Shimizu R; Nuta J; Moribata K; Maeda Y; Muraki Y; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Takifuji K; Yamaue H; Ichinose M
Hepatol Int; 2015 Jan; 9(1):67-75. PubMed ID: 25788381
[TBL] [Abstract][Full Text] [Related]
11. Long-term evaluation of partial splenic embolization followed by interferon therapy in patients with hepatitis C virus (HCV) cirrhosis and thrombocytopenia.
Shimizu H; Takatsuka K; Nakano H; Tenjin T; Fujikawa T; Yoshida A; Yoshimatsu E; Matsui K; Iwabuchi S
Intern Med; 2014; 53(9):925-31. PubMed ID: 24785882
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
13. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
14. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
15. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.
Lee SH; Jin YJ; Shin JY; Lee JW
Medicine (Baltimore); 2017 Jan; 96(1):e5321. PubMed ID: 28072684
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
[TBL] [Abstract][Full Text] [Related]
17. Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.
Choi SB; Lee YJ; Lee JI; Song YJ; Choi BJ; Kim JH; Jung EU; Park SJ; Lee SH; Kim JH; Choi JS; Jee SR; Seol SY
Korean J Hepatol; 2011 Sep; 17(3):183-8. PubMed ID: 22102384
[TBL] [Abstract][Full Text] [Related]
18. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
19. Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.
Harada N; Hiramatsu N; Oze T; Yamada R; Kurokawa M; Miyazaki M; Yakushijin T; Miyagi T; Tatsumi T; Kiso S; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
J Gastroenterol; 2013 Apr; 48(4):535-43. PubMed ID: 22976932
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.
Kogure T; Ueno Y; Fukushima K; Nagasaki F; Kondo Y; Inoue J; Matsuda Y; Kakazu E; Yamamoto T; Onodera H; Miyazaki Y; Okamoto H; Akahane T; Kobayashi T; Mano Y; Iwasaki T; Ishii M; Shimosegawa T
World J Gastroenterol; 2008 Dec; 14(47):7225-4230. PubMed ID: 19084938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
